Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Diverticulitis Disease Market from 2024 to 2025?

The market size for diverticulitis disease has experienced rapid expansion in recent times. The market is projected to increase from $1.85 billion in 2024 to $2.04 billion in 2025, charting a compound annual growth rate (CAGR) of 10.1%. Factors such as an ageing population, dietary patterns, obesity, and improvements in medical imaging technology contributed to the growth during the historic period.

What Is the Projected Market Size of the Diverticulitis Disease Market?

Expectations for the diverticulitis disease market point towards a significant surge in growth in the coming years. The market is projected to reach a worth of $2.92 billion by 2029, developing at a compound annual growth rate (CAGR) of 9.4%. This expected growth over the forecast period is primarily driven by factors such as colonoscopy and endoscopy, greater awareness, minimally invasive procedures, and personalized medicine. Key trends predicted for the same period include preemptive actions, improved diagnostic tools, collaborative healthcare models, and changes in healthcare policies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12990&type=smp

Who are the Major Competitors in the Diverticulitis Disease Market Outlook?

Major companies operating in the diverticulitis disease market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Company, Cipla Limited, Hikma Pharmaceuticals PLC, Endo Pharmaceuticals, Aspen Pharmacare, Zydus Lifesciences, Lupin Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd.

What Is Fueling Growth in the Diverticulitis Disease Market?

The increasing addiction to smoking is predicted to boost the expansion of the diverticulitis disease market. This rise in smoking addiction is fueled by intense promotions, societal acceptability, stress, and the addictive properties of nicotine. The advent of e-cigarettes and vape devices, coupled with societal influences and peer pressure, particularly amongst young individuals, leads to an increased rate of smoking. Smoking enhances the diverticulitis disease treatment by escalating the risk of developing diverticular disease, since it restricts blood circulation to the colon and leads to severe complications, thus increasing the demand for diagnosis and treatment options. For example, in July 2022, as per Statistics Canada, a governmental agency in Canada, there was a 5.8% increase in cigarette production compared to June 2021. Also, there was a 1.3% increase in the total number of cigarettes sold from May 2022, with a count of 1.4 billion in June 2022. Hence, the growing smoking addiction is set to fuel the diverticulitis disease market. The escalating occurrences of diabetes will likely stimulate the forward momentum of the diverticulitis disease market. This increase in diabetes is majorly influenced by factors such as unhealthy diet rich in processed foods, inactive lifestyles, increased obesity rates, genetic susceptibilities, and an ageing population. Diabetes fuels the growth of the diverticulitis treatment by amplifying the risk of complications like weakened blood vessels which can make the colon more susceptible to infections and inflammation, thereby spiking the demand for treatments and therapies. For instance, in June 2024, according to The National Health Service (NHS England), a public-funded healthcare system in the UK, in 2023, the persons diagnosed as pre-diabetic by the NHS in England surged to 3,615,330, an 18% increase from 3,065,825 in 2022. Also, the number of under-40 cases jumped nearly 25%, from 173,166 in 2022 to 216,440 in 2023. Consequently, the rising prevalence of diabetes propels the diverticulitis disease market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12990&type=smp

Which Diverticulitis Disease Market Segments Are Growing the Fastest?

The diverticulitis disease market covered in this report is segmented –

1) By Type: Uncomplicated, Complicated

2) By Diagnosis: Computed Tomography (CT) Scan, Ultrasound, Urine Test, Blood Test

3) By Treatment: Medications, Surgery, Supportive care, Penicillin Antibiotic, Antibiotics, Dietary Supplements, Intravenous (IV) Fluids

4) By End-User: Specialty Centers, Hospitals, Research centers

Subsegments:

1) By Uncomplicated: Outpatient Treatment, Dietary Management, Antibiotic Therapy

2) By Complicated: Hospitalization, Surgical Intervention, Intravenous Antibiotics, Abscess Drainage

Which Industry Trends Are Shaping the Future of the Diverticulitis Disease Market?

Significant players in the diverticulitis disease market are advancing their position by creating novel medications and securing necessary approvals. The process of drug innovation can result in heightened treatment efficacy for diverticulitis, mitigation of complication risks, and enhancement of patient results. In April 2023, Seres’ microbiota drug for recurrent gut infections earned approval from the United States Food and Drug Administration, a US-focused federal establishment. This medication is engineered to tackle recurring gut infections and inhibit the reoccurrence of Clostridioides difficile (C. diff.) infections in adults who are 18 or older. The sanction of Vowst stems from a clinical trial that included 346 patients with recurrent C. diff. infection. The trial revealed that those administered with Vowst drastically had a lower likelihood of getting the infection again in comparison to those who had a placebo. The orally taken medication hinges on microbiota embedding Firmicutes spores, known to augment a robust microbiome that can ward off C. diff. settlement.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report

Which Countries Are Leading the Diverticulitis Disease Market?

North America was the largest region in the diverticulitis disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diverticulitis disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12990

This Report Delivers Insight On:

1. How big is the diverticulitis disease market, and how is it changing globally?

2. Who are the major companies in the diverticulitis disease market, and how are they performing?

3. What are the key opportunities and risks in the diverticulitis disease market right now?

4. Which products or customer segments are growing the most in the diverticulitis disease market?

5. What factors are helping or slowing down the growth of the diverticulitis disease market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model